Armata Pharmaceuticals, Inc. (ARMP) Form 8-K — Aug 12, 2026
Armata Pharmaceuticals reported second quarter 2026 net income of $74.1 million, or $2.02 per basic share, versus a $16.3 million net loss in the year-ago quarter, but the swing was driven almost entirely by a $91.0 million non-cash gain from the change in fair value of its Convertible Loan; diluted EPS was negative at ($0.27). Underlying operations deteriorated: the quarterly operating loss widened to $10.3 million from $6.8 million a year ago as R&D rose to $7.6 million and G&A nearly doubled to $5.2 million on higher stock-based compensation, against grant and award revenue of $2.5 million.
Key figures
- Eps
- $2.02 basic / ($0.27) diluted
- Revenue
- 2510000
- Net Income
- 74141000
- Total Debt
- $283.5 million (convertible loan $163.9M current; term debt $119.6M)
- Revenue Yoy
- 15.7% (vs $2.2M in Q2 2025)
- Total Assets
- 89950000
- Cash Position
- 23952000
- Shares Outstanding
- 37181979
- Dow new funding
- 2500000
- Ga expense q2 2026
- 5236000
- Rnd expense q2 2026
- 7586000
- Basic wavg shares q2
- 36747840
- Grant revenue q2 2025
- 2169000
- Diluted wavg shares q2
- 62041700
- Operating loss q2 2025
- 6844000
- Operating loss q2 2026
- 10312000
- Atm net proceeds h1 2026
- 2373000
- Interest expense q2 2026
- 6634000
- Dow total funding to date
- 28700000
- Term loan funded may 2026
- 25000000
- Net cash used in operating h1 2026
- 14448000
- Non cash fv gain convertible loan q2
- 91018000
Price after filing
Close on the filing date to close N calendar days later (from $4.60). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.